Epizyme Inc. (NASDAQ:EPZM)’s share price was up 2.1% during mid-day trading on Friday . The stock traded as high as $10.03 and last traded at $9.89, with a volume of 133,457 shares changing hands. The stock had previously closed at $9.69.

Several equities analysts have issued reports on EPZM shares. Citigroup Inc. started coverage on shares of Epizyme in a research note on Tuesday, April 5th. They issued a “buy” rating and a $17.00 price objective on the stock. JMP Securities reissued a “buy” rating and issued a $28.00 price objective on shares of Epizyme in a research note on Thursday, June 23rd. Mizuho reissued a “buy” rating and issued a $18.00 price objective on shares of Epizyme in a research note on Monday, June 20th. Wedbush reaffirmed an “outperform” rating and set a $22.00 price target on shares of Epizyme in a research note on Monday, May 9th. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Epizyme in a research note on Tuesday, April 19th. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $23.11.

The firm’s market cap is $561.35 million. The company has a 50 day moving average of $11.00 and a 200-day moving average of $10.79.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.53) by $0.12. Equities research analysts anticipate that Epizyme Inc. will post ($2.25) earnings per share for the current fiscal year.

In related news, insider Robert A. Copeland sold 4,000 shares of the firm’s stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $10.03, for a total transaction of $40,120.00. Following the transaction, the insider now directly owns 4,000 shares in the company, valued at $40,120. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Other large investors recently bought and sold shares of the company. Jennison Associates LLC boosted its stake in Epizyme by 252.4% in the fourth quarter. Jennison Associates LLC now owns 893,913 shares of the biopharmaceutical company’s stock worth $14,320,000 after buying an additional 640,245 shares during the last quarter. Jennison Associates boosted its stake in Epizyme by 0.6% in the third quarter. Jennison Associates now owns 253,668 shares of the biopharmaceutical company’s stock worth $3,262,000 after buying an additional 1,551 shares during the last quarter. Finally, California Public Employees Retirement System bought a new stake in Epizyme during the fourth quarter worth about $2,723,000.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.